130 likes | 136 Vues
Free Preview Lecture <br>"Type 2 Diabetes Tale & Pharmacology: Multilevel Intervention" Online Course on Udemy. <br><br>Discount Coupon: https://www.udemy.com/type-2-diabetes-tale-pharmacology-multilevel-intervention/?couponCode=TYPETWODIABETES <br><br>What you'll learn: <br>Multilevel Intervention, Etiology and Epidemiology of Type 2 Diabetes, Causes of Type 2 diabetes, Three Stages of Type 2 Diabetes, Impaired fasting glucose (IFG) and Impaired glucose tolerance (IGT), A1C Standard and Risk of having Diabetes, The Fruitful Counseling: Management and Posology, Pharmacological Therapy, and Pharmacokinetic & Pharmacodynamic Cases. <br><br>Who this course is for: <br>People from whole of the world, who have an interest in the following approaches: 1) Clinical Pharmacology, 2) Diabetes Research and Clinical Practice, 3) Principles of Organization Behavior, 4) Health Education & Behavior, 5) Health Promotion, 6) Nutrition, 7) Human Learning, 8) Endocrinology and Metabolism, 9) Medical Sciences, 10) Clinical Pharmacokinetics, 11) Autoimmunity, 12) Clinical Chemistry, 13) Clinical Therapy, 14) Biochemistry, 15) Pathology, 16) Laboratory Sciences, 17) Epidemiology, 18) Etiology, 19) Social Science & Medicine, 20) Pharmacotherapy, and 21) Quality Management in Health Care. And this course contains eighty-three resource. <br><br>By Maram Abdel Nasser Taha Shtaya - Pharmacist and American Studies Instructor who is teaching on Udemy.
E N D
Multilevel Intervention Most scientific proof about developing health and health patronage
Multilevel intervention survey catches the promise of more precisely symbolizing real-life conditions
In our depiction of strategies for joining interventions at various standards
Medical nutrition treatment as mentioned by American Diabetes Association et al., (2008):
The late digestion of carbohydrates and split of oligosaccharides
MLI can contemplate other agents and standards that, if left unaddressed
Newly, incretin-related medicines, like (GLP-1) receptor agonists and as well (DPP-4) inhibitors
AGIs might become a reasonable choice as initial-line medicine
Because of our attention in the causal connections between health results and the timing of MLIs